271 related articles for article (PubMed ID: 34462786)
1. Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies.
Sekhri R; Sadjadian P; Becker T; Kolatzki V; Huenerbein K; Meixner R; Marchi H; Wallmann R; Fuchs C; Griesshammer M; Wille K
Ann Hematol; 2021 Nov; 100(11):2707-2716. PubMed ID: 34462786
[TBL] [Abstract][Full Text] [Related]
2. Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
Polverelli N; Elli EM; Abruzzese E; Palumbo GA; Benevolo G; Tiribelli M; Bonifacio M; Tieghi A; Caocci G; D'Adda M; Bergamaschi M; Binotto G; Heidel FH; Cavazzini F; Crugnola M; Pugliese N; Bosi C; Isidori A; Bartoletti D; Auteri G; Latagliata R; Gandolfi L; Martino B; Scaffidi L; Cattaneo D; D'Amore F; Trawinska MM; Stella R; Markovic U; Catani L; Pane F; Cuneo A; Krampera M; Semenzato G; Lemoli RM; Vianelli N; Breccia M; Russo D; Cavo M; Iurlo A; Palandri F
Br J Haematol; 2021 Apr; 193(2):356-368. PubMed ID: 33222197
[TBL] [Abstract][Full Text] [Related]
3. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
[TBL] [Abstract][Full Text] [Related]
4. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
Alvarez-Larrán A; Garrote M; Ferrer-Marín F; Pérez-Encinas M; Mata-Vazquez MI; Bellosillo B; Arellano-Rodrigo E; Gómez M; García R; García-Gutiérrez V; Gasior M; Cuevas B; Angona A; Gómez-Casares MT; Martínez CM; Magro E; Ayala R; Del Orbe-Barreto R; Pérez-López R; Fox ML; Raya JM; Guerrero L; García-Hernández C; Caballero G; Murillo I; Xicoy B; Ramírez MJ; Carreño-Tarragona G; Hernández-Boluda JC; Pereira A;
Cancer; 2022 Jul; 128(13):2441-2448. PubMed ID: 35417564
[TBL] [Abstract][Full Text] [Related]
5. A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis.
Lin JQ; Li SQ; Li S; Kiamanesh EF; Aasi SZ; Kwong BY; Su Chang AL
J Am Acad Dermatol; 2022 Feb; 86(2):339-344. PubMed ID: 34648874
[TBL] [Abstract][Full Text] [Related]
6. The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.
Ikeda K; Ueda K; Sano T; Ogawa K; Ikezoe T; Hashimoto Y; Morishita S; Komatsu N; Ohto H; Takeishi Y
Intern Med; 2017; 56(13):1705-1710. PubMed ID: 28674362
[TBL] [Abstract][Full Text] [Related]
7. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
Nazha A; Gerds AT
Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.
Koschmieder S; Isfort S; Wolf D; Heidel FH; Hochhaus A; Schafhausen P; Griesshammer M; Wolleschak D; Platzbecker U; Döhner K; Jost PJ; Parmentier S; Schaich M; von Bubnoff N; Stegelmann F; Maurer A; Crysandt M; Gezer D; Kortmann M; Franklin J; Frank J; Hellmich M; Brümmendorf TH;
Ann Hematol; 2023 Feb; 102(2):349-358. PubMed ID: 36564535
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database.
Tremblay D; Ronner L; Podoltsev N; Gotlib J; Heaney M; Kuykendall A; O'Connell C; Shammo JM; Fleischman A; Mesa R; Yacoub A; Hoffman R; Moshier E; Zubizarreta N; Mascarenhas J
Leuk Res; 2021 Oct; 109():106629. PubMed ID: 34082375
[TBL] [Abstract][Full Text] [Related]
10. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
11. Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.
Maffioli M; Mora B; Passamonti F
Clin Adv Hematol Oncol; 2017 Sep; 15(9):700-707. PubMed ID: 28949941
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group.
Pepe S; Rossi E; Trawinska M; Tatarelli C; Di Veroli A; Maurillo L; Romano A; Crescenzi SL; di Toritto TC; Tafuri A; Latagliata R; Scalzulli E; Andriani A; De Stefano V; Breccia M
Ann Hematol; 2022 Jun; 101(6):1275-1282. PubMed ID: 35318505
[TBL] [Abstract][Full Text] [Related]
13. An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms.
Curto-Garcia N; Harrison CN
Future Oncol; 2018 Jan; 14(2):137-150. PubMed ID: 29056075
[TBL] [Abstract][Full Text] [Related]
14. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ
Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib.
Bjørn ME; Hasselbalch HC
Expert Rev Hematol; 2017 May; 10(5):393-404. PubMed ID: 28402197
[TBL] [Abstract][Full Text] [Related]
16. Disseminated blastomycosis in a patient with polycythemia vera on ruxolitinib.
Zeitler K; Jariwala R; Alrabaa S; Sriaroon C
BMJ Case Rep; 2021 Nov; 14(11):. PubMed ID: 34725058
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and Safety of Ruxolitinib in Polycythemia Vera].
Chang L; Duan MH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1515-1518. PubMed ID: 36208258
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
Verstovsek S; Passamonti F; Rambaldi A; Barosi G; Rosen PJ; Rumi E; Gattoni E; Pieri L; Guglielmelli P; Elena C; He S; Contel N; Mookerjee B; Sandor V; Cazzola M; Kantarjian HM; Barbui T; Vannucchi AM
Cancer; 2014 Feb; 120(4):513-20. PubMed ID: 24258498
[TBL] [Abstract][Full Text] [Related]
19. Real-World Dosing Patterns of Ruxolitinib in Patients With Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea.
Altomare I; Parasuraman S; Paranagama D; Kish J; Lord K; Yu J; Colucci P
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e915-e921. PubMed ID: 34353779
[TBL] [Abstract][Full Text] [Related]
20. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.
Ruella M; Salmoiraghi S; Risso A; Carobbio A; Buttiglieri S; Spatola T; Sivera P; Ricca I; Barbui T; Tarella C; Rambaldi A
Exp Hematol; 2013 Jul; 41(7):627-34. PubMed ID: 23542632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]